Navigation Links
Amylin Pharmaceuticals Highlights 2009 Value Creation Opportunities
Date:1/12/2009

Product and Operational Targets Presented At JPMorgan Healthcare Conference

SAN FRANCISCO, Jan. 12 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) today announced product and operational targets for 2009 that provide the opportunity to transform diabetes and obesity treatment and position the Company to be cash flow positive by the end of 2010. The news was presented by Daniel M. Bradbury, president and chief executive officer, at the JPMorgan Healthcare Conference in San Francisco, CA.

"The epidemics of diabetes and obesity, which synergistically contribute to cardiovascular disease, are the major health crises of our lifetime," said Bradbury. "The significant unmet need in the diabetes and obesity markets provides an opportunity for Amylin's first-in-class therapies to create tremendous benefit. We look to 2009 to further improve health outcomes for patients, physicians and payors, and to increase shareholder value."

2009 CORPORATE TARGETS

During his remarks, Bradbury highlighted the key 2009 value creation opportunities for Amylin. These targets include the following:

  • Gain approval for an expanded indication of BYETTA as a monotherapy, finalize label updates and return the product to growth
  • Leverage knowledge gained from BYETTA to submit the New Drug Application (NDA) for exenatide once weekly and execute the DURATION head-to-head clinical program designed to show comparative superiority
  • Continue growing SYMLIN revenue
  • Complete obesity clinical trials with amylin/leptin analogs and finalize obesity development and funding strategy
  • Improve operating results and make significant progress toward achieving positive operating cash flow by the end of 2010
'/>"/>
SOURCE Amylin Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Amylin Pharmaceuticals to Present at BioCentury NewsMakers Conference, Thomas Weisel Healthcare Conference and Bear Stearns Healthcare Conference
2. Drs. John Patton of Nektar, Igor Gonda of Aradigm, Tomas Landh of Novo Nordisk, Chris Rhodes of Amylin to Speak at iiBIGs Plenary Panel in Vegas
3. Amylin Pharmaceuticals Reports Third Quarter Financial Results
4. Amylin Pharmaceuticals to Present at BIOCOM Investor Conference
5. Amylin Pharmaceuticals Elects Adrian Adams to Board of Directors
6. Xenome Receives a Syndicated US$10 Million Equity Investment from Queensland BioCapital Fund, Amylin Pharmaceuticals and Innovis Investment Partners
7. Amylin Pharmaceuticals to Present at Nasdaq 20th Investor Program
8. Amylin Pharmaceuticals to Present at Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
9. Amylin Pharmaceuticals to Webcast First Quarter Results
10. Amylin Pharmaceuticals to Present at Morgan Stanley Global Healthcare Unplugged Conference
11. Amylin Pharmaceuticals Announces Time Change to Previously Announced Presentation at the Morgan Stanley Global Healthcare Unplugged Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)...   Niagara Thermal Products is proud to announce ... LLC ("B3") as the critical thermal component supplier in ... Army Corps of Engineers.  B3 has developed the only ... and destroys VOCs and other chemical pollutants, allergens and ...
(Date:1/15/2014)... England and SAN JOSE, California ... international biotechnology company developing antibody-drug conjugates for cancer, today announced ... Board of Directors. Dr Reynolds has over 20 years, development ... Medical Officer at Seattle Genetics. "I am delighted ...
(Date:1/15/2014)... , January 15, 2014 A study ... races on the Formula 1 track could help to tackle ... Applied Technologies (MAT), Stowhealth (a GP surgery based in Stowmarket) ... healthcare provider Simplyhealth. Telemetry technology, which is inspired ...
(Date:1/15/2014)... The Microcompetition with Foreign DNA theory explains how latent ... viruses is the Epstein Barr Virus (EBV), and one of ... a chronic inflammatory disease that destroys the body’s joints. As ... have high concentrations of EBV DNA in their bodies (1). ...
Breaking Biology Technology:Niagara Thermal Products LLC Selected as Critical Supplier for Buffalo BioBlower Air Purification Systems 2Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 2Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 3Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 2Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 3Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 4Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3
... , , , , ... at 1 p.m. EDT, Sunday, Aug. 23, to discuss new science experiments ... from NASA,s Kennedy Space Center in Florida and will be broadcast live ... ) , , Media are invited to ...
... Md., Aug. 20 Martek Biosciences Corporation (Nasdaq: MATK ... supply agreement with Milk Powder Solutions, based in Australia. Under the ... exclusive supplier for all of its ARA needs for infant formula ... , , "This new agreement with Milk Powder ...
... - Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI ; ... Option(TM) Inferior Vena Cava (IVC) Filter in the United ... limited pre-launch in July. Angiotech holds exclusive worldwide rights ... it obtained in a license agreement with privately held ...
Cached Biology Technology:NASA Sets Briefing on New Space Station Science Experiments 2Martek Signs Sole-Source Supply Agreement with Milk Powder Solutions 2Martek Signs Sole-Source Supply Agreement with Milk Powder Solutions 3Angiotech Pharmaceuticals announces the commercial launch of the Option(TM) Inferior Vena Cava Filter in the United States 2Angiotech Pharmaceuticals announces the commercial launch of the Option(TM) Inferior Vena Cava Filter in the United States 3Angiotech Pharmaceuticals announces the commercial launch of the Option(TM) Inferior Vena Cava Filter in the United States 4Angiotech Pharmaceuticals announces the commercial launch of the Option(TM) Inferior Vena Cava Filter in the United States 5
(Date:7/9/2014)... cooks are turning to more healthful alternatives to their ... sometimes mean low satisfaction. Now researchers are reporting new ... that are made with olive oil rather than pork ... of Agricultural and Food Chemistry . , Ana M. ... to expect just the right amount of chewiness and ...
(Date:7/9/2014)... fossil from China challenges the commonly held belief that ... ability to fly. The birdlike fossil is actually not ... remains of a tiny tree-climbing animal that could glide, ... in Blanding, Utah, and Alan Feduccia of the University ... Journal of Ornithology . , The fossil of the ...
(Date:7/9/2014)... developed by researchers at the NIH,s National ... its collaborators to treat sickle cell disease ... business. The drug candidate, Aes-103, is the ... molecular mechanism of sickle cell disease. Baxter ... required for regulatory approval and commercialization. , ...
Breaking Biology News(10 mins):Researchers declassify dinosaurs as being the great-great-grandparents of birds 2First drug candidate from NIH program acquired by biopharmaceutical company 2First drug candidate from NIH program acquired by biopharmaceutical company 3First drug candidate from NIH program acquired by biopharmaceutical company 4
... announced a partnership with Toyota to support efforts ... of the Philippines Peablanca Protected Landscape and Seascape ... of the nations main islands. In addition ... additional benefits from agroforestry projects under the three-year ...
... Questions remain unresolved as to whether the Neanderthals ... or because of deteriorating climatic conditions. Although scientists ... has been difficult to pinpoint the climatic character ... new study by an international team of researchers, ...
... This release is available in German . , ... the climate and ecosystem of the Arctic Ocean,Bremerhaven, September 13, ... one metre thick this year, equating to an approximate 50 ... the initial results from the latest Alfred-Wegener-Institute for Polar and ...
Cached Biology News:Conservation International and Toyota partner to protect Philippines' rain forests 2Conservation International and Toyota partner to protect Philippines' rain forests 3Climate -- no smoking gun for Neanderthals 2The sea ice is getting thinner 2The sea ice is getting thinner 3The sea ice is getting thinner 4
... COOLSCOPE is an integrated digital microscope and ... computer, equipment setup, optical adjustment or software ... innovative technology, COOLSCOPE combines simplicity and advanced ... COOLSCOPE offers simultaneous viewing of a macro ...
... kit provides complete components including positive ... detection of DNA fragmentation in cultured ... of BrdU in the procedure provides ... methods. Results can be analyzed by ...
... Life Science LAS-3000 imaging system combines ... simplified user interface, providing significantly improved ... of modularities. The system is especially ... perfect standard system for Western blotting ...
... Science LAS-3000mini is a compact image ... applications, and the perfect standard system ... LAS-3000 provides significantly improved system sensitivity ... calibration standards validate that Fujis LAS-3000 ...
Biology Products: